# OnCo record yl211 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/yl211/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "yl211" ;
  schema:name "YL211"@en ;
  schema:description "YL211 is an experimental antibody-drug conjugate aimed at c-MET, a protein on some solid tumours. MediLink Therapeutics licensed worldwide rights to Roche in January 2024, and it is in a first phase 1 trial."@en ;
  schema:url <https://onco.cc/drugs/yl211/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://1stoncology.com/blog/?p=92748>, <https://clinicaltrials.gov/study/NCT06384352> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "deal-asset" ;
  onco:modality "Antibody-drug conjugate (c-MET)" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/met/> ;
  onco:companies <https://onco.cc/companies/medilink/>, <https://onco.cc/companies/roche-genentech/> ;
  onco:trials <https://onco.cc/trials/nct06384352/> .